The Hubrecht lab is also involved in two trials to assess whether
colon cancer organoids grown from individual patients can predict drug response.
Not exact matches
To demonstrate that ability, the MIT team delivered
organoids with a mutated form of the APC gene, which is the
cancer - initiating mutation in 80 percent of
colon cancer patients.
In the new paper, the researchers used CRISPR to introduce
cancer - causing mutations into the
organoids and then delivered them via colonoscopy to the
colon, where they attached to the lining and formed tumors.
The HUB also maintains large biobanks of
colon -, breast -, lung - and pancreas
cancer organoids, accessible by academia and industry.